NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
BigBear.ai Holdings
BBAI
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
DNTH Dianthus Therapeutics
- 21.600
- +0.550+2.61%
Close Feb 28 16:00 ET
- 21.600
- 0.0000.00%
Post 16:20 ET
639.29MMarket Cap-9.45P/E (TTM)
21.740High20.650Low378.34KVolume20.880Open21.050Pre Close8.05MTurnover2.92%Turnover RatioLossP/E (Static)29.60MShares33.77052wk High1.89P/B279.84MFloat Cap18.34552wk Low--Dividend TTM12.96MShs Float336.000Historical High--Div YieldTTM5.18%Amplitude5.136Historical Low21.283Avg Price1Lot Size
About Dianthus Therapeutics Company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Company Profile
SymbolDNTH
Company NameDianthus Therapeutics
Listing DateJun 21, 2018
Founded2015
CEOMr. Marino Garcia
MarketNASDAQ
Employees53
Fiscal Year Ends12-31
Address7 Times Square,43rd Floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-929-999-4055
Websitehttp://dianthustx.com
Company Executives
- Name
- Position
- Salary
- Marino Garcia
- President, Chief Executive Officer and Director
- --
- Ryan Savitz
- Chief Financial Officer, Chief Business Officer and Treasurer
- --
- Edward G. Carr
- Chief Accounting Officer
- --
- Dr. Simrat Randhawa, M.D.
- Chief Medical Officer
- --
- Adam M. Veness
- Senior Vice President, General Counsel and Secretary
- --
- Leon O. Moulder, Jr
- Chairman of the Board
- --
- Dr. Steven Joseph Romano, M.D.
- Director
- --
- Dr. Jonathan Violin, M.B.A.,PhD
- Director
- --
- Paula Soteropoulos
- Independent Director
- --
- Anne M. McGeorge
- Independent Director
- --
- Tomas Kiselak
- Independent Director
- --
- Alison F. Lawton
- Independent Director
- --